Literature DB >> 2540427

Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues.

P J Tremblay1, F Pothier, T Hoang, G Tremblay, S Brownstein, A Liszauer, P Jolicoeur.   

Abstract

Transgenic mice carrying the v-Ha-ras oncogene under the control of the mouse mammary tumor virus long terminal repeat were produced. These mice exhibit several phenotypes: mammary tumors, bilateral hyperplasia of the harderian lacrimal gland, primary bronchio-alveolar lung adenocarcinoma, and splenomegaly. High levels of the transgene RNA were detected in mammary, harderian, and lung tumors. Accumulation of cells of the myeloid lineages was found in enlarged spleens. This phenotype may represent an indirect effect of v-Ha-ras expression on myeloid progenitors. Our data illustrate the cell-specific effects of v-Ha-ras.

Entities:  

Mesh:

Year:  1989        PMID: 2540427      PMCID: PMC362668          DOI: 10.1128/mcb.9.2.854-859.1989

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  35 in total

1.  Specific activation of the cellular Harvey-ras oncogene in dimethylbenzanthracene-induced mouse mammary tumors.

Authors:  S Dandekar; S Sukumar; H Zarbl; L J Young; R D Cardiff
Journal:  Mol Cell Biol       Date:  1986-11       Impact factor: 4.272

2.  Spleen specific expression of an MMTV related transcript associated with the Mtv-6 locus in BALB/c mice.

Authors:  A Sarkar; W H Günzburg
Journal:  Virology       Date:  1986-10-15       Impact factor: 3.616

3.  Mitogenic effects of the proto-oncogene and oncogene forms of c-H-ras DNA in human diploid fibroblasts.

Authors:  C K Lumpkin; J E Knepper; J S Butel; J R Smith; O M Pereira-Smith
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

4.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.

Authors:  E Sinn; W Muller; P Pattengale; I Tepler; R Wallace; P Leder
Journal:  Cell       Date:  1987-05-22       Impact factor: 41.582

5.  Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas.

Authors:  C Theillet; R Lidereau; C Escot; P Hutzell; M Brunet; J Gest; J Schlom; R Callahan
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

6.  Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas.

Authors:  C J Der; G M Cooper
Journal:  Cell       Date:  1983-01       Impact factor: 41.582

7.  High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients.

Authors:  R Lidereau; C Escot; C Theillet; M H Champeme; M Brunet; J Gest; R Callahan
Journal:  J Natl Cancer Inst       Date:  1986-09       Impact factor: 13.506

8.  Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice.

Authors:  A C Andres; C A Schönenberger; B Groner; L Hennighausen; M LeMeur; P Gerlinger
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

9.  A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.

Authors:  H Hirai; Y Kobayashi; H Mano; K Hagiwara; Y Maru; M Omine; H Mizoguchi; J Nishida; F Takaku
Journal:  Nature       Date:  1987 Jun 4-10       Impact factor: 49.962

10.  Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus.

Authors:  A L Huang; M C Ostrowski; D Berard; G L Hager
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

View more
  34 in total

1.  A transgenic, mesodermal specific, Dkk1 mouse model recapitulates a spectrum of human congenital limb reduction defects.

Authors:  Filemon Dela Cruz; Melissa Terry; Igor Matushansky
Journal:  Differentiation       Date:  2012-03-08       Impact factor: 3.880

Review 2.  Factors controlling the expression of mouse mammary tumour virus.

Authors:  W H Günzburg; B Salmons
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

Review 3.  Interrogating mouse mammary cancer models: insights from gene expression profiling.

Authors:  Antonio A Fargiano; Kartiki V Desai; Jeffrey E Green
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-07       Impact factor: 2.673

Review 4.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

5.  The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues.

Authors:  L Stepanova; M Finegold; F DeMayo; E V Schmidt; J W Harper
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

6.  Cellular aging is a critical determinant of primary cell resistance to v-src transformation.

Authors:  N Tavoloni; H Inoue
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells.

Authors:  N E Hynes; D Taverna; I M Harwerth; F Ciardiello; D S Salomon; T Yamamoto; B Groner
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

Review 8.  Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer.

Authors:  W J Muller
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

9.  Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic Mice.

Authors:  Zhuona Rong; Tingting Fan; Huiling Li; Juan Li; Kangwei Wang; Xinxin Wang; Jianyi Dong; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Mol Cell Proteomics       Date:  2017-05-16       Impact factor: 5.911

Review 10.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.